Appearance of acute myelogenous leukemia [AML] in a patient with breast cancer after adjuvant chemotherapy: case report and review of the literature
Iranian Journal of Cancer Prevention. 2015; 8 (2): 125-128
en En
| IMEMR
| ID: emr-161876
Biblioteca responsable:
EMRO
Acute Myelogenous Leukemia [AML] is an aggressive hematologic malignancy that cause by abnormal proliferation and accumulation of hematopoietic progenitor cells. A 37-year-old woman referred to oncologic clinic with a self-detected mass and pain in her left breast. The stage of tumor was IIIA. She was treated with the combination of anthracycline and cyclophosphamide for four courses, followed by four courses of paclitaxel with trastuzumab for one year. After 18 months of the first treatment for breast cancer, her bone marrow biopsy was compatible with AML-M2. Here, we are reporting a young woman case with breast cancer that developed AML malignancy during short interval of therapy
Buscar en Google
Índice:
IMEMR
Asunto principal:
Neoplasias de la Mama
/
Literatura de Revisión como Asunto
/
Quimioterapia Adyuvante
/
Paclitaxel
/
Antraciclinas
/
Ciclofosfamida
/
Anticuerpos Monoclonales Humanizados
Límite:
Female
/
Humans
Idioma:
En
Revista:
Iran. J. Cancer Prevention
Año:
2015